RFP 124-26 Lab Drug Testing

Active BD-27-1206-40000-40000-135345 RFPHealthcare & MedicalMassachusetts Bay Transportation Authority
The full text, documents and contacts of this bid come with a ProposalWorkspace plan.Get started

At a glance

Massachusetts Bay Transportation Authority (Massachusetts) posted this RFP on Nov 12, 2026. Responses are due Dec 8, 2026. Category: Healthcare & Medical. Questions are due 2026-11-24 14:00. Solicitation number BD-27-1206-40000-40000-135345.

Solicitation details

General information

Solicitation number
BD-27-1206-40000-40000-135345
Notice type
RFP
Place of performance
Massachusetts
Questions due
2026-11-24 14:00

Agency and category

Agency
Massachusetts Bay Transportation Authority
Category
009Healthcare & Medical
Source listing
Link with a plan

About this listing

ProposalWorkspace summary

This bid was found on the agency's procurement portal. The portal's own text is not republished here; the summary below was written by ProposalWorkspace's AI from the bid documents. The full posting is on the portal - subscribe to get the link.

Summary

AI-read from the bid documents

Summary fields on this page were extracted by AI from the bid documents. Always verify dates, amounts and requirements against the official solicitation.

What the bid is for

The Massachusetts Bay Transportation Authority (“MBTA” or “Authority”) seeks a laboratory that will provide DOT and Non-DOT drug testing for MBTA employees and applicants.

The MBTA may at its own discretion award contract(s) to one or multiple Bidders.

Scope

The selected laboratory shall provide DOT and Non-DOT drug testing for MBTA employees and applicants.

All DOT testing shall comply with 49 CFR Part 40, all applicable DOT agency regulations, and the HHS Mandatory Guidelines.

All Non-DOT testing shall follow the DOT testing process—including drug panel, initial and confirmation testing, specimen validity testing, and cutoff concentrations—unless otherwise directed by MBTA.

The laboratory shall be capable of analyzing and reporting the following specimen outcomes:

  • Negative
  • Non-negative requiring confirmation
  • Confirmed positive
  • Dilute negative; non-negative dilute requiring confirmation
  • Adulterated
  • Substituted
  • Invalid
  • Cancelled

The laboratory shall:

  • Clearly identify and report DOT and Non-DOT tests separately.
  • Provide all documentation and supporting information required by the MRO or designee and MBTA for review and final reporting.

The selected laboratory shall provide secure, reliable electronic transmission of drug testing results to MBTA’s existing Drug Program system.

The laboratory shall collaborate with MBTA and its designated system provider to establish and maintain an electronic data exchange that ensures accurate, timely, and complete transfer of all testing information.

The laboratory shall maintain documented downtime procedures to ensure uninterrupted reporting and provide backup reporting methods that allow MBTA to receive results and documentation when electronic transmission is unavailable.

The proposer shall identify expected end-to-end turnaround times covering each stage of the testing process: Specimen courier collection Laboratory receipt Laboratory testing Result transmission to the MRO.

The contractor shall provide or coordinate secure, reliable transportation of specimens from all MBTA collection locations to the designated laboratory, including routine courier service with daily weekday pickups (Monday–Friday) during business hours at multiple MBTA sites, overnight transportation for time-sensitive specimens, after-hours transportation, weekend and holiday transportation, and emergency STAT/post-accident transportation when requested by MBTA, with shipment tracking.

Additional information

**Submission method:** Responses shall be submitted via **COMMBUYS**. Bidder is required to prepare and submit all required documents to MBTA electronically via COMMBUYS.

Each Response shall be submitted in the following two parts:

  • Technical Response including: Bid Cover Letter, Power of Attorney, *Form A: Pre-Award Bidder Evaluation Data Form*, *Form B: Technical Response*, *Form C: Small Business Program Attestation Form*, Proof of Insurance
  • Price Response as a separate document, including: *Form D: Bidder Price Response*

The Technical Response and Price Response shall be completely separate documents.

The MBTA will evaluate Responses based on a combination of Pass/Fail Criteria, Technical Evaluation Criteria, and Price Responses. Each Bidder must obtain a “pass” on all Pass/Fail Evaluation Criteria (Legal and Financial Stability, based on *Form A*) in order for its Response to be eligible for selection.

Technical Evaluation Criteria:

  • Turnaround Time Requirements (15%)
  • DOT & Non-DOT Testing Capability (25%)
  • System Integration & Electronic Data Exchange (17.5%)
  • Courier & Specimen Transportation (17.5%)
  • Supplier Diversity (25%)

The successful bidder shall provide proof of all required insurance within three business days of conditional notice of award.

From and after the Response Due Date the MBTA shall have one hundred and eighty (180) calendar days to award a Contract based on this RFP.

Virtual presentations are scheduled for the week of 1/11/2027. Contract execution and service start date are estimated 2/2/2027.

Documents

4 files

Subscribe to get these 4 documents.

  • RFP 124-26 Lab Drug Testing.pdf
    Download
  • RFP 124-26 Lab Drug Testing Scope of Services.pdf
    Download
  • Form D Bidder Price Response.pdf
    Download
  • Exhibit A - MBTA Minimum Insurance Requirements~13.pdf
    Download

Similar open bids

In Massachusetts

More from Massachusetts Bay Transportation Authority

Open bids